Moderna completed enrollment of Cytomegalovirus vaccine (mRNA-1647) phase 2 study
On Mar. 3, 2020, Moderna announced that enrollment was complete for all three dose cohorts of the Phase 2 dose-confirmation study of its investigational cytomegalovirus (CMV) vaccine (mRNA-1647).
mRNA-1647, the first mRNA vaccine for an infectious disease to enter a Phase 2 study, was a wholly owned program in Moderna’s prophylactic vaccines portfolio.
Tags:
Source: Moderna
Credit: Photo: Cytomegalovirus (CMV) infection of a lung pneumocyte, courtesy: Centers for Disease Control and Prevention Public Health Image Library, 1982.
